RxDoctor Payments Data

Joseph Murrow, MD

Internal Medicine · Louisville, KYNPI 1316996739

Payments from drug & device makers

$7,974in general payments, 2019–2025

Across 91 payments — averaging $87.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$770
  • GSK$588
  • Amarin Pharma, Inc.$511
  • Pfizer$371
  • Esperion Therapeutics, Inc.$308
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$7,956100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,974 in reported general payments places this provider in the 90th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$124,421
Medicare patients
195
Services billed
1,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide51$65,184
JardianceEmpagliflozin50$55,266
EliquisApixaban38$33,669
OzempicSemaglutide21$21,216
JanuviaSitagliptin Phosphate12$6,762
Repatha SureclickEvolocumab11$6,116
SynthroidLevothyroxine Sodium40$4,011
VascepaIcosapent Ethyl11$3,560
Rosuvastatin Calcium151$1,936
Losartan Potassium220$1,904
Atorvastatin Calcium277$1,842
Dextroamphetamine Sulfate ErDextroamphetamine Sulfate13$1,528
Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide64$1,242
Amlodipine Besylate243$1,232
Simvastatin138$1,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$276$65,18451 claims
Boehringer IngelheimJardiance$269$55,26650 claims
PfizerEliquis$371$33,66938 claims
Novo NordiskOzempic$237$21,21621 claims
AbbVieSynthroid$770$4,01140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →